271 related articles for article (PubMed ID: 20715855)
1. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
Kim I; Kim TH; Ma K; Lee ES; Kim D; Oh KT; Lee DH; Lee KC; Youn YS
Bioconjug Chem; 2010 Aug; 21(8):1513-9. PubMed ID: 20715855
[TBL] [Abstract][Full Text] [Related]
2. Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics.
Kim TH; Jiang HH; Lee S; Youn YS; Park CW; Byun Y; Chen X; Lee KC
Bioconjug Chem; 2011 Apr; 22(4):625-32. PubMed ID: 21401109
[TBL] [Abstract][Full Text] [Related]
3. Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.
Kim TH; Jiang HH; Lim SM; Youn YS; Choi KY; Lee S; Chen X; Byun Y; Lee KC
Bioconjug Chem; 2012 Nov; 23(11):2214-20. PubMed ID: 23116483
[TBL] [Abstract][Full Text] [Related]
4. A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action.
Kim I; Kim TH; Ma K; Park ES; Oh KT; Lee ES; Lee KC; Youn YS
Regul Pept; 2011 Apr; 167(2-3):239-45. PubMed ID: 21329731
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia.
Lee J; Lee C; Kim I; Moon HR; Kim TH; Oh KT; Lee ES; Lee KC; Youn YS
Int J Pharm; 2012 Mar; 424(1-2):50-7. PubMed ID: 22226877
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.
Kim TH; Park CW; Kim HY; Chi MH; Lee SK; Song YM; Jiang HH; Lim SM; Youn YS; Lee KC
Biol Pharm Bull; 2012; 35(7):1076-83. PubMed ID: 22791155
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.
Lee J; Lee C; Kim TH; Chi SC; Moon HR; Oh KT; Lee ES; Lee KC; Youn YS
Regul Pept; 2012 Aug; 177(1-3):68-72. PubMed ID: 22561689
[TBL] [Abstract][Full Text] [Related]
8. Trimeric PEG-Conjugated Exendin-4 for the Treatment of Sepsis.
Lee W; Park EJ; Kwak S; Lee KC; Na DH; Bae JS
Biomacromolecules; 2016 Mar; 17(3):1160-9. PubMed ID: 26905040
[TBL] [Abstract][Full Text] [Related]
9. Decanoic acid-modified glycol chitosan hydrogels containing tightly adsorbed palmityl-acylated exendin-4 as a long-acting sustained-release anti-diabetic system.
Lee C; Choi JS; Kim I; Byeon HJ; Kim TH; Oh KT; Lee ES; Lee KC; Youn YS
Acta Biomater; 2014 Feb; 10(2):812-20. PubMed ID: 24140611
[TBL] [Abstract][Full Text] [Related]
10. Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
Son S; Lim SM; Chae SY; Kim K; Park EJ; Lee KC; Na DH
Int J Pharm; 2015 Nov; 495(1):81-86. PubMed ID: 26325318
[TBL] [Abstract][Full Text] [Related]
11. A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.
Zhang L; Wang L; Meng Z; Gan H; Gu R; Wu Z; Gao L; Zhu X; Sun W; Li J; Zheng Y; Dou G
Biochem Biophys Res Commun; 2014 Mar; 445(2):511-6. PubMed ID: 24565847
[TBL] [Abstract][Full Text] [Related]
12. Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
Zhong X; Yang S; Liu T; Ji S; Hu J; Li H
Eur J Med Chem; 2018 Apr; 150():841-850. PubMed ID: 29597167
[TBL] [Abstract][Full Text] [Related]
13. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.
Kim H; Lee J; Kim TH; Lee ES; Oh KT; Lee DH; Park ES; Bae YH; Lee KC; Youn YS
Pharm Res; 2011 Aug; 28(8):2008-19. PubMed ID: 21472489
[TBL] [Abstract][Full Text] [Related]
14. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes.
Kim H; Park H; Lee J; Kim TH; Lee ES; Oh KT; Lee KC; Youn YS
Biomaterials; 2011 Feb; 32(6):1685-93. PubMed ID: 21126761
[TBL] [Abstract][Full Text] [Related]
15. Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system.
Lee J; Lee C; Kim TH; Lee ES; Shin BS; Chi SC; Park ES; Lee KC; Youn YS
J Control Release; 2012 Aug; 161(3):728-34. PubMed ID: 22634071
[TBL] [Abstract][Full Text] [Related]
16. PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.
Sun Z; Tong G; Kim TH; Ma N; Niu G; Cao F; Chen X
Theranostics; 2015; 5(3):240-50. PubMed ID: 25553112
[TBL] [Abstract][Full Text] [Related]
17. Poly(ethylene glycol)-conjugated human serum albumin including iron porphyrins: surface modification improves the O2-transporting ability.
Huang Y; Komatsu T; Wang RM; Nakagawa A; Tsuchida E
Bioconjug Chem; 2006; 17(2):393-8. PubMed ID: 16536471
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4 improves the oral glucose tolerance in diabetic rats: pancreas regeneration, better function of pancreatic islets, or impaired glucose uptake?
Strauss A; Moskalenko V; Chodnevskaja I; Timm S; Thiede A; Otto C; Ulrichs K
Transplant Proc; 2008 Mar; 40(2):533-5. PubMed ID: 18374122
[TBL] [Abstract][Full Text] [Related]
19. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS
Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850
[TBL] [Abstract][Full Text] [Related]
20. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
